Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2002-09-11
2010-06-29
Schwadron, Ron (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S143100, C424S144100, C424S155100, C424S153100, C424S156100, C424S172100, C424S174100, C530S388220, C530S388730, C530S388800, C530S388850, C530S867000
Reexamination Certificate
active
07744877
ABSTRACT:
Disclosed herein are methods of depleting peripheral blood B cells in a human host comprising administering to the host an immunologically active anti-CD20 antibody in an amount effective to deplete peripheral blood B cells in the host.
REFERENCES:
patent: 4831175 (1989-05-01), Gansow
patent: 4975278 (1990-12-01), Senter et al.
patent: 5099069 (1992-03-01), Gansow
patent: 5124471 (1992-06-01), Gansow
patent: 5246692 (1993-09-01), Gansow
patent: 5286850 (1994-02-01), Gansoh
patent: 5439665 (1995-08-01), Hansen
patent: 5460785 (1995-10-01), Rhodes
patent: 5500362 (1996-03-01), Robinson et al.
patent: 5595721 (1997-01-01), Kaminski
patent: 5648267 (1997-07-01), Reff
patent: 5677180 (1997-10-01), Robinson et al.
patent: 5686072 (1997-11-01), Uhr et al.
patent: 5693780 (1997-12-01), Newman et al.
patent: 5721108 (1998-02-01), Robinson et al.
patent: 5736137 (1998-04-01), Anderson
patent: 5776456 (1998-07-01), Anderson
patent: 5843398 (1998-12-01), Kaminski et al.
patent: 5843439 (1998-12-01), Anderson
patent: 6015542 (2000-01-01), Kaminski et al.
patent: 6090365 (2000-07-01), Kaminski et al.
patent: 6120767 (2000-09-01), Robinson et al.
patent: 6183744 (2001-02-01), Goldenberg
patent: 6287537 (2001-09-01), Kaminski et al.
patent: 6306393 (2001-10-01), Goldenberg
patent: 6399061 (2002-06-01), Anderson
patent: 6455043 (2002-09-01), Grillo-López
patent: RE38008 (2003-02-01), Abrams
patent: 6565827 (2003-05-01), Kaminski et al.
patent: 6652852 (2003-11-01), Robinson et al.
patent: 6682734 (2004-01-01), Anderson
patent: 6893625 (2005-05-01), Robinson et al.
patent: 2002/0009444 (2002-01-01), Grillo-Lopez
patent: 2002/0197255 (2002-12-01), Anderson et al.
patent: 2003/0021781 (2003-01-01), Anderson et al.
patent: 2003/0026804 (2003-02-01), Grillo-Lopez
patent: 2003/0082172 (2003-05-01), Anderson et al.
patent: 2003/0095963 (2003-05-01), Anderson et al.
patent: 2003/0147885 (2003-08-01), Anderson
patent: 2003/0206903 (2003-11-01), Grillo-Lopez
patent: 2004/0167319 (2004-08-01), Teeling
patent: 2004/0213784 (2004-10-01), Grillo-Lopez et al.
patent: 2005/0163708 (2005-07-01), Robinson et al.
patent: 2005/0186205 (2005-08-01), Anderson et al.
patent: 2006/0034835 (2006-02-01), Adams
patent: 0 125 023 (1984-11-01), None
patent: 0 125 023 (1984-11-01), None
patent: 0 173 494 (1986-03-01), None
patent: 0 274 394 (1988-07-01), None
patent: 0 274 394 (1988-07-01), None
patent: 0 682 040 (1995-11-01), None
patent: 0 682 040 (1995-11-01), None
patent: 0 451 216 (1996-01-01), None
patent: 0 669 836 (1996-03-01), None
patent: 0 752 248 (1997-01-01), None
patent: 0 125 023 (2002-03-01), None
patent: 87/ 02671 (1987-05-01), None
patent: WO 88/04936 (1988-07-01), None
patent: 89/ 00999 (1989-02-01), None
patent: WO 91/04320 (1991-04-01), None
patent: WO 92/07466 (1992-05-01), None
patent: WO 93/02108 (1993-02-01), None
patent: WO 94/11026 (1994-05-01), None
patent: 00/ 09160 (2000-02-01), None
patent: 00/ 27428 (2000-05-01), None
patent: 00/ 27433 (2000-05-01), None
patent: 01/ 10460 (2001-02-01), None
patent: 2004/ 056312 (2004-07-01), None
Badger, et al. “Experimental Radioimmunotherapy of Murine Lymphoma with131I-labeled Anti-T-Cell Antibodies.” Cancer Research, 46, pp. 6223-6228, 1986.
Buchsbaum, et al. “Improved Delivery of Radiolabeled Anti-B1 Monoclonal Antibody to Raji Lymphoma Xenografts by Predosing with Unlabeled Anti-B1 Monoclonal Antibody.” Cancer Research; 52, pp. 637-642, 1992.
Chen, et al. “Tumor Idiotype Vaccines. VI. Synergistic Anti-Tumor Effects with Combined “Internal Image” Anti-Idiotypes and Chemotherapy.” Journal of Immunology, 143, pp. 1053-1057, No. 3, 1989.
Clark et al, “Role of the Bp35 cell surface polypeptide in human B-cell activation.” Immunobiology, vol. 82, pp. 1766-1770, 1985.
Clark, et al. “Phase Evaluation of the Anti-Bp35 Antibody Induces Human B Cell Proliferation: Implications for in Vivo Immunotherapy.” Journal Cellular Biochemistry Supp. 9A, p. 63, 1985.
DeNardo, et al. “Fractionated Radioimmunotherapy of B-cell Malignancies with 131I-Lym-1.” Cancer Research (Suppl) 50, pp. 1014s-1016s, 1990.
Kaminski, et al. “Initial Clinical Radioimmunotherapy Results with131-I-Anti-B1 (Anti-CD20) in Refractory B-Cell Lymphoma.” Antibody Immimoconjugates, and Radiopharmaceuticals vol. 5, No. 3 p. 345, 1992.
Kaminski, et al. “131-I Anti-B1: Initial Clinical Evaluation in B-Cell Lymphoma.” Third Conference on Rid and Rit of Cancer, Abstract. No. 144, 1990.
Langmuir, “Radioimmunotherapy: Clinical Results and Dosimetric Considerations.” Nuclear Medicine Biology vol. 19, No. 2, pp. 213-225, 1992.
Levy, et al. “Tumor Therapy with Monoclonal Antibodies.” Federation Proceedings 42:9 pp. 2650-2656, 1983.
Macklis, et al. “Radiobiologic Sutdies of Low-Dose-Rate90Y-Lymphoma Therapy.” Cancer Supplement, vol. 73, No. 3, pp. 966-973, 1994.
Maloney, et al. “Monoclonal Anti-Idiotype Antibody Therapy of B-Cell Lymphoma: The Addition of a Short Course of Chemotherapy Does Not Interfere with the Antitumor Effect Nor Prevent the Emergence of Idiotype-Negative Variant Cells.” Blood, vol. 80, No. 6, pp. 1502-1510, 1992.
Masucci, et al. “Chemotherapy and Immunotherapy of Colorectal Cancer.” Medical Oncology Tumor Pharmacother vol. 8, No. 3, pp. 207-220, 1991.
Nadler, et al. “A Unique Cell Surface Antigen Identifying Lymphoid Malignancies of B Cell Origin.” Journal of Clinical Investigative, vol. 67, pp. 134-140, 1981.
Reilly, “Radioimmunotherapy of malignancies.” Clinical Pharmacy, vol. 10, pp. 359-375, 1991.
Press, et al. Scientific Proceedings, ASCO, Abstrict No. 864, 1986.
See-Lasley, et al. “Hodgkin's Disease and Non-Hodgkin's Lymphoma Nitrogen mustard, vincristine (Oncovin), procarbazine, and prednisone (MOPP).” Manual of Oncology Therapeutics, C.V. Mosby Company, pp. 44-71, 1981.
Senter, et al. “Enhancement of the in vitro and in vivo Antitumor Activities of Phosphorylated Mitomycin C and Etoposide Derivatives by Monoclonal Antibody-Alkaline Phosphatase Conjugates.” Cancer Research 49, pp. 5789-5792, 1989.
Stashenko, et al. “Characterization of Human B Lymphocyte-Specific Antigen.” The Journal of Immunology vol. 125, No. 4, pp. 1678-1685, 1960.
Chinn, et al. “Production and characterization of radiolabeled anti-CD20 monoclonal antibody: potential application to treatment of B-cell lymphoma.” Proceedings of the American Medical Association for Cancer Research, vol. 33, Abstract 2012, p. 337, 1992.
Classon, et al. “The Primary Structure of the Human Leukocyte Antigen CD37, A Species Homologue of the Rat MRC OC-44 Antigen.” The Journal of Experimental Medicine, vol. 169, No. 4, pp. 1497-1502, 1989.
DeNardo, et al. “Requirements for a Treatment Plan in System for Radioimmunotherapy.” International Journal of Radiation Oncology Biology Physics, vol. 11, No. 2, pp. 335-348, 1985.
Kaminski, et al. “Radioimmunotherapy (RIT) of Refractory B-Cell Lymphoma with 131-I-Anti-B1 (Anti-CD20) Antibody: Promising Early Results Using Non-Marrow Ablative Radiation Doses.” Blood, Abstract 161, p. 162.
Langmuir, “Radiommunotherapy: Clinical Results and Dosimetric Considerations.” Nuclear Medicine and Biology, vol. 19, No. 2, pp. 213-225, 1992.
Larson, et al. “Comparison of Bone Marrow Dosimetry and Toxic Effect of High Dose131I-labeled Monoclonal Antibodies Administered to Man.” Nuclear Medicine and Biology, vol. 16, No. 2, pp. 153-158, 1989.
Leichner, et al. “Tumor dosimetry in radioimmunotherapy: Methods of calculation for beta particles.” Medical Physics, vol. 20, No. 2, Pt.2, pp. 529-534, 1993.
Leichner, et al. “Dosimetry and Treatment Planning in Radioimmunotherapy.” Frontiers of Radiation Therapy and Oncology, vol. 24, pp. 109-120, 1990.
Link, et al. “A Unique Antigen on Mature B-Cells Defined by a Monoclonal Antibody.”
Anderson Darrell R.
Hanna Nabil
Leonard John E.
Newman Roland A.
Rastetter William H.
Biogen Idec Inc.
Schwadron Ron
Sidley Austin LLP
LandOfFree
Expression and use of anti-CD20 Antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Expression and use of anti-CD20 Antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Expression and use of anti-CD20 Antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4243969